Todd C. Brady, M.D., Ph.D.

Todd C. Brady, M.D., Ph.D.

President and Chief Executive OfficeratAldeyra Therapeutics· In proxies 2022–2025

Pay in FY2023+29% from the year before · Aldeyra Therapeutics stock -49.6% the same year

Todd C. Brady, M.D., Ph.D. was paid $3.7M in FY2023 (Dec), up 29%. Aldeyra Therapeutics stock fell 49.6% that year.

Pay$100 in the stock at the end of FY21 → $88
Pay is from the Summary Compensation Table of each Aldeyra Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Aldeyra TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -83%
  2. Evoke Pharma, Inc.Public company
    • Director? – 2025No stock prices for these years
  3. F-star Therapeutics, Inc.Public company
    • Director? – 2023No stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?